Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Aug;79(15):9572-8.
doi: 10.1128/JVI.79.15.9572-9578.2005.

Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021)

Christophe Delaunay  1 , Françoise Brun-Vézinet, Roland Landman, Gilles Collin, Gilles Peytavin, Aldo Trylesinski, Philippe Flandre, Michael Miller, Diane Descamps
Affiliations
Clinical Trial

Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021)

Christophe Delaunay et al. J Virol. 2005 Aug.

Abstract

Tonus was a pilot study in which previously untreated human immunodeficiency virus type 1 (HIV-1)-infected patients received the combination of abacavir, lamivudine, and tenofovir once a day. There was a high rate of early virological failure, and the M184V and K65R mutations were frequently detected at week 12 (W12). The objective of this study was to examine the selection dynamics of the K65R and M184V/I mutations. Bulk sequencing of the reverse transcriptase (RT) gene was performed on plasma HIV-1 RNA at baseline, W4, and W12 for 21 patients with detectable viral loads. The RT genes from baseline, W4, and W12 plasma samples from five patients who developed both M184V and K65R but with different mutational patterns were also cloned and screened for the K65R mutation by selective real-time PCR. At baseline, bulk sequencing and clonal analysis showed only wild-type RT sequences. At W4, M184V/I was detected in 12/19 patients and K65K/R in 2 patients by bulk sequencing. At W12, M184V/I was found in 18/20 patient, together with the K65R in 13 patients. At W4, clonal analysis revealed the K65R mutation in 0.6 to 48% of clones in the five patients studied. At W12, the K65R mutation was found in 30 to 100% of clones. K65R and M184V/I seemed to arise in separate clones, followed by an enrichment of viruses containing both mutations. The clinical relevance of this independent evolution is unclear. M184V/I was selected more frequently than K65R at W4. However, K65R was also detected early using a clone-sensitive genotyping method. All three nucleoside analogs are known to select the K65R and/or M184V/I mutation. This convergent genetic pathway to resistance, associated with lower antiretroviral potency, may explain the high selection rate of these mutations in this trial.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Bulk sequencing at baseline (day −14) and weeks 4 and 12, compared to clonal sequencing at weeks 4 and 12, for five patients. WT, wild type.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Amiel, C., A. Kara, V. Schneider, G. Pialoux, W. Rozembaum, and J. C. Nicolas. 2004. The K65R mutation in tenofovir-naïve patients: frequent association with Q151M mutation, abstr. 627. In Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, Alexandria, Va.
    1. Deval, J., K. L. White, M. D. Miller, N. T. Parkin, J. Courcambeck, P. Halfon, B. Selmi, J. Boretto, and B. Canard. 2004. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 279:509-516. - PubMed
    1. Fang, G., G. Zhu, H. Burger, J. S. Keithly, and B. Weiser. 1998. Minimizing DNA recombination during long RT-PCR. J. Virol. Methods 76:139-148. - PubMed
    1. Farthing, C., H. Khanlou, and V. Yeh. 2003. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naïve HIV-infected patients, abstr. 43. In Antiviral Therapy, 2003, vol. 8, suppl. 1. International Medical Press, London, United Kingdom.
    1. Gallant, J. E., A. E. Rodriguez, W. Weinberg, B. Young, D. Berger, M. L. Lim, Q. Liao, L. Ross, J. Johnson, and M. S. Shaefer. 2003. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis, abstr. H-1722a. In Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.

Publication types

MeSH terms